发表文章

名中医工作室

第一作者论文：（时间倒序）

  1. 张蓓，黄圆圆.中医治疗鼻咽癌临证经验及研究进展. Journal of Oncology in Chinese Medicine，May2019，Vol.1 No.1.
  2. 张蓓,汪桃利,黄圆圆,丘惠娟,胡丕丽,王艳玲. 初诊鼻咽癌中医证型与临床分期及EBV-DNA相关性研究[J]. 中国中西医结合耳鼻咽喉科杂志,2011,06:404-407.
  3. 张蓓. 脑转移瘤的中西医结合治疗进展[J]. 癌症进展,2008,03:216-221.
  4. 张蓓. 生存质量和中医整体观在肿瘤疗效评价中的意义[J]. 中医药管理杂志,2007,01:56-58.
  5. 张蓓 ，黄国贤，张亚奇，陈徐贤，胡丕丽，徐伯平加味四君子汤防治肝癌介入治疗后储备功能损伤的临床研究，中药材，2004，27（5）：387~389
  6. 张蓓 ，胡丕丽，丘惠娟，钱穗毅，陈徐贤，黄国贤，升板方治疗化疗后血小板减少的疗效观察，癌症，2004，23（11s）：1470~1472
  7. 张蓓 ，胡丕丽，黄国贤，丘惠娟，陈徐贤，钱穗毅，补气活血中药对鼻咽癌综合治疗后青紫舌的影响，中药材，2004，27（9）：701~703
  8. 张蓓 ，黄国贤，胡丕丽，丘惠娟，钱穗毅，陈徐贤，活血利咽汤防治鼻咽癌同期放化疗中口咽急性毒性反应51例，中医杂志，2004，45（8）：605
  9. 张蓓 ，胡丕丽，黄国贤，丘惠娟，陈徐贤，钱穗毅，鼻咽清毒颗粒防治鼻咽癌急性放射性口咽炎疗效观察，广东医学，2003，24（6）：658~659
  10. 张蓓 ，胡丕丽，黄国贤，丘惠娟，陈徐贤，钱穗毅，不同治则中药治疗鼻咽癌放疗后青紫舌的临床研究，新中医，2003，35（5）：29~30
  11. 张蓓 ，胡丕丽，丘惠娟，陈徐贤，黄国贤，徐伯平，艾迪配合化疗治疗非小细胞肺癌临床疗效观察，肿瘤防治杂志，2003，10（5）：510~511
  12. 张蓓,胡丕丽. 中西医结合治疗对肿瘤患者生存质量的影响[J]. 中华肿瘤杂志,2003,03:98-100.
  13. 张蓓,胡丕丽,丘惠娟,陈徐贤,黄国贤,徐伯平. 升板方治疗肿瘤化疗后血小板减少症的临床观察[J]. 广东医学,2001,10:972
  14. 张蓓,黄火文. 肝转移癌的中西医治疗[J]. 医学理论与实践,1999,02:56-58.
  15. 张蓓,黄火文,徐伯平,陈徐贤,胡丕丽,李连华,黄国贤. 利咽灵防治急性放射性口咽炎临床研究[J]. 中医杂志,1997,10:611-612.
  16. 张蓓,陈效莲,黄伙文. 鼻咽癌放疗后青紫舌患者远期疗效观察[J]. 中医杂志,1990,04:29-30.
  17. Zhang B, Chen XL, Huang HW. BSERVATION ON LONG-TERM THERAPEUTIC EFFECT IN NASOPHARYNGEAL CARCINOMA PATIENTS WITH CYANOSIS OF TONGUE AFTER RADIOTHERAPY. 《Journal of Traditional Chinese Medicine》 1991( 01)
  18. 张蓓,黄火文,陈效莲. 鼻咽癌放疗并用祛瘀生津冲剂的血液流变学及微循环的观察[J]. 广州医药,1990,05:19-21.

 

通讯作者论文：（时间倒序-中医类）

  1. 范腾，黄圆圆，张蓓.中医防治肿瘤的研究进展.日中医学2022年8月第37卷第2期44-47.
  2. 阚钧, 周瑞生, 张蓓. “带瘤生存”与“节拍化疗”的碰撞与思考. 中医肿瘤学杂志, 2021,3(06):18-21.
  3. 黄圆圆，权琦，陈平，雷孟洁，张蓓.鼻咽癌患者91例放化疗后应用中药维持治疗的安全性报告.中华中医药杂志（原中国医药学报）2020年8月第35卷第8期3902-3905.
  4. 戎煜明，于礼建，张蓓.张蓓辨治肿瘤中医学术思想概述.新中医，2020年6月第52卷第11期205-207.
  5. 于礼建，戎煜明，黄圆圆，张蓓.张蓓教授治疗鼻咽癌经验.河北中医2020年4月第42卷第4期503-506.
  6. 雷孟洁，黄圆圆，胡巧珍，张蓓.核桃健脑片对东莨菪碱诱导记忆障碍小鼠的作用及其机制考察. 中国药师2018 年第21 卷第9 期China Pharmacist 2018，Vol． 21 No． 9,1538-1541.
  7. 戎煜明，林晓平，林俊忠，黄金圣，丘惠娟，张蓓.通络化瘀方对增强高级别脑胶质瘤化疗敏感性的影响. 中国处方药 2018年第16 卷 第11 期,1-3.
  8. 李婷炜, 张蓓. 乳腺癌术前中医证型与预后因素的相关性研究, 实用医学杂志2017年第33卷第9期160-162.
  9. 陈平，黄圆圆，权琦，张蓓. 名中医张蓓治疗鼻咽癌临床经验拾要，世界中西医结合杂志,2017年12月，Vol.12，No.11：1505-1507.
  10. 陈平，黄圆圆，李婷炜，丘惠娟,张蓓. 初诊鼻咽癌患者的血清CRP水平与中医辨证分型的关系. 实用中西医结合临床杂志，2017年6月，Vol.17 NO.6：39-41.
  11. 严正, Research of Brucea javanica against Cancer. Chin J Integr Med. DOI: 10.1007/s11655-016-2501-6.
  12. 詹文婷，丘惠娟，黄圆圆，严正，陈平，夏云飞，张蓓 ，鼻咽癌中医分型与影像学特征及疗效相关性研究，实用医学杂志，2012，28（19）：3295~3297
  13. 戎煜明，张蓓 ，吴慧瑜，丘惠娟，胡丕丽，钱穗毅，注射用黄芪多糖减轻Ⅱ期结肠癌化疗副反应临床观察，中药材，2011，34（4）：657~659
  14. 王艳玲，张蓓 ，汪桃利，黄圆圆，丘惠娟，詹文婷，中医辨证分型对鼻咽癌患者预后的影响，辽宁中医杂志，2011，38（9）：1822~1824
  15. 黄圆圆，张蓓 ，胡丕丽，丘惠娟，王艳玲，詹文婷，滋元灵拮抗吉西他滨所致小鼠骨髓抑制的实验研究，中药材，2010，33（6）：976~979
  16. 钱穗毅，张蓓 ，胡丕丽，卢震海，黄圆圆，丘惠娟，大肠癌患者舌苔脱落细胞EGFR表达与舌象的关系，中华肿瘤防治杂志，2010，17（17）：1348~1350
  17. 汪桃利，张蓓 ，黄圆圆，丘惠娟，戎煜明，王艳玲，大剂量生南星治疗鼻咽癌的毒性学研究，中药材，2009，32（5）：829~831

 

SCI类:

  1. Efficacy of Aidi injection combined with chemotherapy, radiotherapy or chemoradiotherapy for unresectable esophageal cancer treatment: A meta-analysis and systematic review of 29 randomized controlled trials. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023 Jun;79(6):707-722.(IF 3.064)
  2. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med.2022 Jul;12(7):e989. (IF 8.554)
  3. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway. Thorac Cancer.2022 Fen;13(7):1027-1039 (IF 3.223)
  4. Efficacy of the Nourishing Yin and Clearing Heat Therapy Based on Traditional Chinese Medicine in the Prevention and Treatment of Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinomas: A Systematic Review and Meta-Analysis of Thirty Randomized Controlled Trials. Evid-Based Compl Alt.2022 Apr 19;4436361.(IF 2.65)
  5. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. J Immunother Cancer. 2021 Nov;9(11):e003431.(IF 13.751)
  6. Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study. Radiother Oncol. 2021 Aug;161:83-91.(IF 6.28)
  7. Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting. Front Oncol. 2021 Sep 21;11:698732.(IF 6.244)
  8. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Cancer Immunology Immunotherapy. 2021 Jul 23.(IF 6.968)
  9. He-Chan Pian inhibits the metastasis of non-small cell lung cancer via the miR-205-5p-mediated regulation of the GREM1/Rap1 signaling pathway. Phytomedicine, 2021,94:153821.(IF 5.34)
  10. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Curr. Oncol. 2020 Dec,28(1),209–219.(IF 3.677)
  11. An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. Clinical Cancer Research，2020 Dec 1.(IF 8.911)
  12. New first-line treatment strategies for advanced lung squamous cell carcinoma. Transl Lung Cancer Res.2020 Apr;9(2):414-417.(IF 5.132)
  13. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: An observational retrospective study. Sci Rep.2020 Jul23;10(1):12336.(IF 3.998)
  14. Changes in colorectal cancer incidence by site and age from 1973 to 2015: a SEER database analysis. Aging Clin Exp Res.2020 Oct 6.(IF 2.697)
  15. Safety and efficacy of long-term zoledronic acid in advanced breast cancer with bone metastasis in south China. J Oncol.2020 Sep 30;2020:5670601.(IF 2.206)
  16. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019 Jul 12;7(1)(IF 8.676)
  17. The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers. Journal of Oncology，2019, 1568465.(IF 2.6)
  18. Cutaneous extranodal natural killer (NK) / T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases. Leuk Res.2019 Nov 30;88:106284.(IF 2.066)
  19. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. Journal of Cancer2019; 10(27)): 6858-6864.(IF 3.182)
  20. Positive impact of the negative lymph node count on the survival rate of stage III colon cancer with pN1 and right-side disease. J Cancer. 2019 Jan 29;10(4):1052-1059.(IF 3.182)
  21. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncol Lett. 2019 Feb;17(2):2335-2343.(IF 1.871)
  22. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy. Transl Cancer Res  2019 May 8（4）1137-1147.(IF 1.07)
  23. Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study. Aging(Albany NY),2018 Dec 28. 10.18632/aging.101700.(IF 5.179)
  24. Brain metastases in newly diagnosed colorectal cancer: a population-based study. cancer Management and research, 2018 Nov 15; 10:5649-5658.(IF 3.702)
  25. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair‑proficient and ‑deficient colorectal cancer. ONCOLOGY LETTERS. Published online on: December 12, 2018. https://doi.org/10.3892/ol.2018.9826.(IF 1.664)
  26. Rechallenge of oxaliplatin-containing regimens in the third-or later-line therapy for patients with heavily treated metastatic  colorectal cancer. OncoTargets and Therapy，2018:11 2467–2473.(IF 2.656)
  27. Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer. Oncotarget,2017 Oct 12;8(58):99136-99149.(IF 5.168)
  28. Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis1. Transl Oncol. 2017 Apr;10(2):288-294.(IF 3.025)
  29. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. J Cancer. 2017 May 12;8(8):1410-1416.(IF 2.916)
  30. Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide. Oncology Letters.2017.7488 2024-2030.(IF 1.4)
  31. Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients. Oncotarget. 2016 Apr 12;7(15):21034-45.(IF 5.008)
  32. Decreased apolipoprotein A-I levels indicate poor prognosis in extranodal natural killer/T-cell lymphoma, nasal type. OncoTargets and Therapy. 2016 Mar 14;9:1281-90.(IF 2.272)
  33. The MMP-7-181A/G gene polymorphism is a prognostic indicator in patients with gastric cancer. Translational Cancer Research 2016-10
    doi:10.21037/tcr.2016.10.04.(IF  1.757)
  34. Jiang L, Wang L, Li PF, Zhang XK, Chen JW, Qiu HJ, Wu XD, Zhang B*. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. OncoTargets and Therapy, 2015:8 1451-1457.(IF 2.311)
  35. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. Onco Targets Ther. 2015 Sep 1;8:2407-13.(IF  2.311)
  36. Jiang L,Wang L,Li PF,Zhang XK,Chen JW,Qiu HJ,Wu XD,Zhang B*. Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. MEDICAL ONCOLOGY, 2014 (10), 31:218.(IF 2.058)
  37. Jiang L, Li PF, Xiao ZZ, Qiu HJ, Zhang XK, Xiao YB, Zhang B*. Prognostic factors of primary pulmonary mucoepidermoid carcinoma: a clinical and pathological analysis of 34 cases. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014; 7 (10): 6792-6799.(IF 1.783)
  38. Jiang C, Liao FX, Rong YM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ, Chen XX, Zhang B, Xia LP, Zhang B*. Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014; 15 (13): 5493.(IF 1.5)
  39. Ping Chen, Bei Zhang, Guifang Guo, Liangping Xia, Huijuan Qiu. Efficacy comparison between Hepatic Arterial Chemotherapy plus Systemic Chemotherapy Used as first-line and non-first-line btween hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Chinese-German J Clin Oncol, May 2014, Vol. 13, No. 5, 229–P23
  40. Postoperative Chemoradiotherapy versus Postoperative Chemotherapy for Completely Resected Gastric Cancer with D2 Lymphadenectomy: A Meta-Analysis. PLOS ONE.2013 2013;8(7):e689396.(IF 3.73)
  41. 陈平，夏良平，张蓓. 癌细胞中葡萄糖转运与代谢特点. 肿瘤学杂志，2013，19(7):565-569.
  42. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013;30(1):439. (IF 2.15)
  43. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013;15(8):e443-52.(IF 2.08)
  44. Nasopharyngeal carcinoma in children and adolescents in an endemic area: A report of 185 cases. Int J of Pedi Otorh. 2013;77(9):1545-1460.(IF 1.35)
  45. Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients  with advanced gastric cancer: a report of 14 cases. Chinese-German J Clin Oncol, 2013 01, (12): 30-34.